Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2019 4
2020 5
2021 5
2022 4
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Persistence of Anti-SARS-CoV-2 Spike IgG Antibodies Following COVID-19 Vaccines.
Alharbi NK, Al-Tawfiq JA, Alwehaibe A, Alenazi MW, Almasoud A, Algaisi A, Alhumaydhi FA, Hashem AM, Bosaeed M, Alsagaby SA. Alharbi NK, et al. Among authors: almasoud a. Infect Drug Resist. 2022 Jul 29;15:4127-4136. doi: 10.2147/IDR.S362848. eCollection 2022. Infect Drug Resist. 2022. PMID: 35937784 Free PMC article.
Immunogenicity of High-Dose MVA-Based MERS Vaccine Candidate in Mice and Camels.
Alharbi NK, Aljamaan F, Aljami HA, Alenazi MW, Albalawi H, Almasoud A, Alharthi FJ, Azhar EI, Barhoumi T, Bosaeed M, Gilbert SC, Hashem AM. Alharbi NK, et al. Among authors: almasoud a. Vaccines (Basel). 2022 Aug 17;10(8):1330. doi: 10.3390/vaccines10081330. Vaccines (Basel). 2022. PMID: 36016218 Free PMC article.
Seroprevalence of SARS-CoV-2 among high-risk healthcare workers in a MERS-CoV endemic area.
Alroqi F, Masuadi E, Alabdan L, Nogoud M, Aljedaie M, Abu-Jaffal AS, Barhoumi T, Almasoud A, Alharbi NK, Alsaedi A, Khan M, Arabi YM, Nasr A. Alroqi F, et al. Among authors: almasoud a. J Infect Public Health. 2021 Sep;14(9):1268-1273. doi: 10.1016/j.jiph.2021.08.029. Epub 2021 Aug 25. J Infect Public Health. 2021. PMID: 34479078 Free PMC article.
Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial.
Bosaeed M, Balkhy HH, Almaziad S, Aljami HA, Alhatmi H, Alanazi H, Alahmadi M, Jawhary A, Alenazi MW, Almasoud A, Alanazi R, Bittaye M, Aboagye J, Albaalharith N, Batawi S, Folegatti P, Ramos Lopez F, Ewer K, Almoaikel K, Aljeraisy M, Alothman A, Gilbert SC, Khalaf Alharbi N. Bosaeed M, et al. Among authors: almasoud a. Lancet Microbe. 2022 Jan;3(1):e11-e20. doi: 10.1016/S2666-5247(21)00193-2. Epub 2021 Nov 3. Lancet Microbe. 2022. PMID: 34751259 Free PMC article. Clinical Trial.
Seroprevalence of MERS-CoV in healthy adults in western Saudi Arabia, 2011-2016.
Degnah AA, Al-Amri SS, Hassan AM, Almasoud AS, Mousa M, Almahboub SA, Alhabbab RY, Mirza AA, Hindawi SI, Alharbi NK, Azhar EI, Hashem AM. Degnah AA, et al. Among authors: almasoud as. J Infect Public Health. 2020 May;13(5):697-703. doi: 10.1016/j.jiph.2020.01.001. Epub 2020 Jan 28. J Infect Public Health. 2020. PMID: 32005618 Free PMC article.
Humoral Immunogenicity and Efficacy of a Single Dose of ChAdOx1 MERS Vaccine Candidate in Dromedary Camels.
Alharbi NK, Qasim I, Almasoud A, Aljami HA, Alenazi MW, Alhafufi A, Aldibasi OS, Hashem AM, Kasem S, Albrahim R, Aldubaib M, Almansour A, Temperton NJ, Kupke A, Becker S, Abu-Obaidah A, Alkarar A, Yoon IK, Azhar E, Lambe T, Bayoumi F, Aldowerij A, Ibrahim OH, Gilbert SC, Balkhy HH. Alharbi NK, et al. Among authors: almasoud a. Sci Rep. 2019 Nov 8;9(1):16292. doi: 10.1038/s41598-019-52730-4. Sci Rep. 2019. PMID: 31705137 Free PMC article.
18 results